-
Bacterial Vesicle-Based Rapid mRNA Antigen Display for Tumor
2026-07-20
Li et al. introduce a rapid, customizable tumor vaccine platform using engineered bacterial outer membrane vesicles to display and deliver mRNA antigens. This strategy offers an alternative to lipid nanoparticles, enabling efficient dendritic cell targeting and potent antitumor immunity.
-
Cy5-UTP: Illuminating Single-Molecule RNA Dynamics in R-Loop
2026-07-20
Explore how Cy5-UTP (Cyanine 5-uridine triphosphate) enables single-molecule visualization and advanced RNA labeling for dissecting R-loop–mediated genome instability. This article dives deep into practical assay design, referencing the latest imaging breakthroughs and APExBIO’s product innovation.
-
Sulfo-NHS-SS-Biotin: Practical Guide for Cleavable Protein L
2026-07-19
Sulfo-NHS-SS-Biotin provides a water-soluble, amine-reactive solution for selective and reversible labeling of proteins—especially cell surface proteins—enabling efficient purification and analysis. It is best suited for workflows requiring gentle, membrane-impermeable biotinylation with the option for subsequent label removal. It is not appropriate for labeling intracellular proteins or for applications needing stable biotin attachment under reducing conditions.
-
LY2228820: p38 MAP Kinase Inhibitor for Advanced Research
2026-07-18
LY2228820 empowers precise dissection of p38 MAPK-driven inflammation and tumor biology, elevating both anti-inflammatory and cancer research workflows. Its robust selectivity and flexible protocol parameters enable researchers to streamline signaling pathway analyses and unlock new experimental possibilities.
-
Spleen-Targeted mRNA Vaccines Drive ISG15+ T Cell Immunity i
2026-07-17
Lin et al. develop a spleen-targeted neoantigen mRNA vaccine (STNvac) that elicits robust ISG15+ CD8+ T cell responses and tertiary lymphoid structure formation in hepatocellular carcinoma (HCC). This study elucidates a mechanistic link between organ-specific mRNA delivery and antitumor immunity, providing a foundation for next-generation mRNA vaccine strategies against poorly immunogenic cancers.
-
FXR-KLF11 Axis Suppresses JAK2/STAT3 in Contrast-Induced AKI
2026-07-17
This study uncovers a renoprotective mechanism in contrast-induced acute kidney injury (CI-AKI) involving FXR-mediated transcriptional upregulation of KLF11, which inhibits the JAK2/STAT3 inflammatory pathway. These findings elucidate a targeted molecular axis for CI-AKI prevention and provide foundational insight for the development of FXR agonist-based therapeutics.
-
Targeting Immunoproteasome Heterogeneity: ONX-0914 for Trans
2026-07-16
Explore how the selective immunoproteasome inhibitor ONX-0914 (PR-957) enables translational researchers to dissect proteasome pool heterogeneity and cytokine modulation in autoimmune and inflammatory models. This article integrates mechanistic insights, strategic experimental guidance, and the implications of recent breast cancer proteasome research, positioning ONX-0914 as a key tool for high-fidelity disease modeling and therapeutic innovation.
-
Mubritinib Reveals OXPHOS Dependency in AML via Complex I In
2026-07-16
Baccelli et al. (2019) identified Mubritinib (TAK 165) as a selective inhibitor of mitochondrial complex I, showing potent anti-leukemic activity in chemotherapy-resistant acute myeloid leukemia (AML) specimens with high oxidative phosphorylation (OXPHOS) activity. This study provides a molecular rationale for targeting OXPHOS in specific AML subtypes and opens new avenues for therapeutic intervention.
-
Veratridine: Voltage-Gated Sodium Channel Opener in Research
2026-07-15
Veratridine, a benchmark voltage-gated sodium channel opener, empowers precise interrogation of sodium channel dynamics and excitotoxicity across neuroscience and oncology workflows. APExBIO’s high-purity Veratridine uniquely supports robust assay fidelity, advanced mechanistic dissection, and translational innovation for drug discovery.
-
ML385: NRF2 Inhibitor Workflows for Cancer and Redox Researc
2026-07-15
ML385 offers selective, potent NRF2 inhibition, empowering researchers to dissect antioxidant pathways and therapeutic resistance in cancer and redox biology. This guide details experimental protocols, troubleshooting best practices, and novel applications—including ferroptosis and inflammation studies—anchored in recent evidence.
-
Carboplatin in 3D Cancer Models: Proteomic Insights for Onco
2026-07-14
Explore how Carboplatin, a leading platinum-based DNA synthesis inhibitor, reveals new dynamics in cancer cell response within 3D tumor models. This article delivers advanced guidance for preclinical oncology research and highlights proteomic findings that inform assay design and drug resistance strategies.
-
PTEN mRNA Reinstatement: Redefining Oncology with EZ Cap™
2026-07-14
Explore the mechanistic and translational advances enabled by EZ Cap™ Human PTEN mRNA (ψUTP), a pseudouridine-modified, Cap1-structured in vitro transcribed mRNA. This article contextualizes its superiority for cancer research, especially in overcoming PI3K/Akt-driven resistance, and provides actionable protocol guidance for translational researchers.
-
Hemagglutinin mRNA Vaccine Protects Dairy Cows from H5N1
2026-07-13
This study establishes that a hemagglutinin-based mRNA–lipid nanoparticle vaccine provides robust and durable protection against H5N1 influenza in lactating dairy cows, with no adverse effects on health or milk production. The research highlights the promise of mRNA vaccine platforms for large livestock and their potential in mitigating zoonotic influenza threats.
-
GTP Solution in mRNA Synthesis: Catalyzing Translational Bla
2026-07-13
Explore how high-purity GTP Solution (100 mM) enables next-generation mRNA synthesis for localized bladder cancer therapy. This article connects mechanistic insight, workflow innovation, and translational impact—highlighting recent advances in p21 mRNA-LNP delivery, experimental best practices, and strategic guidance for researchers seeking clinical relevance.
-
Flubendazole: Autophagy Modulation Tool for Cancer & Fibrosi
2026-07-12
Flubendazole (methyl N-[6-(4-fluorobenzoyl)-1H-benzimidazol-2-yl]carbamate) is a high-purity autophagy activator widely used in cancer biology and cellular degradation research. Its robust DMSO solubility and well-characterized mechanism make it a benchmark for autophagy modulation studies. Recent evidence links autophagy regulation with metabolic pathways relevant to liver fibrosis and cancer.